News
Arcturus Therapeutics receives Orphan Drug Designation from U.S. FDA for cystic fibrosis treatment
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for Arcturus Therapeutics' product candidate ARCT-032 to treat cystic fibrosis (CF).
The FDA’s...
Novo Nordisk invests in expansion of Chartres production facilities
Novo Nordisk is set to invest more than 16 billion Danish kroner (2.1 billion euros) to expand its existing production site in Chartres, France,...
FDA approves first therapy for rare type of non-cancerous tumors
The U.S. Food and Drug Administration has approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is...
